Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.

abstract：:We and others previously demonstrated that human multiple myeloma (MM) cells express CD40 and have an active CD40-growth regulatory pathway. This study characterizes the growth outcome of soluble (gp39) or membrane-bound recombinant human CD40-ligand (rCD40L) and its relationship with Fas-dependent apoptosis. Contrary...

journal_title：Leukemia & lymphoma

authors： Tong AW,Seamour B,Chen J,Su D,Ordonez G,Frase L,Netto G,Stone MJ

更新日期：2000-02-01 00:00:00

abstract：:There is insufficient information on the characteristics of chronic lymphocytic leukemia (CLL) in Latin American patients. Immunoglobulin variable-region heavy-chain (IGVH) gene usage and mutation status and prognostic factors were investigated in patients resident in Venezuela. The most frequently used IGVH family ge...

journal_title：Leukemia & lymphoma

authors： Marquez ME,Deglesne PA,Lopez JL,Da Costa O,Borrego M,Hernández M,Muller A,Ajchenbaum-Cymbalista F,Romano E

更新日期：2012-02-01 00:00:00

abstract：:Chromosomal analysis of stimulated whole blood cells and purified B lymphocytes was performed in 13 stage A(0) and 1 stage C(IV) chronic lymphocytic leukemia (B-CLL) patients. Abnormal clones were found in 6 cases in purified B lymphocytes cultures and in a single one in whole blood cultures. In situ hybridization wit...

journal_title：Leukemia & lymphoma

authors： Brizard A,Brizard F,Dreyfus B,Morel F,Lecron JC,Tanzer J,Preud'Homme JL

更新日期：1993-11-01 00:00:00

abstract：:To assess parameters of therapeutic response and survival after the onset of the blastic phase (BP) in 47 patients with Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML), a number of clinical hematologic, and cytogenetic data at the BP were evaluated. Among the eleven parameters examined, only the c...

journal_title：Leukemia & lymphoma

authors： Sadamori N,Yao E,Mine M,Tokunaga S,Matsunaga M,Nakamura H,Sasagawa I,Itoyama T,Kawachi T,Sandberg AA

更新日期：1991-01-01 00:00:00

abstract：:We compared bcl-2 with P-glycoprotein expression (C494 and JSB1), and both with ex vivo chemosensitivity by Differential Staining Cytotoxicity (DiSC) assay (25 cytotoxic drugs), in 76 fresh haematological specimens, including 51 chronic lymphocytic leukaemias (CLL). Strong correlations were seen between bcl-2 and Pgp ...

journal_title：Leukemia & lymphoma

authors： Bosanquet AG,Bell PB,Burlton AR,Amos TA

更新日期：1996-12-01 00:00:00

abstract：:Plasma cell tumors show an increased incidence in HIV-positive patients. The cases reported in the literature suggest that plasma cell tumors occur in a younger age group than that encountered in the general population. Pathologically, many of these tumors show a plasmablastic morphology. Plasma cell tumors in HIV-pos...

journal_title：Leukemia & lymphoma

authors： Salarieh A,Rao C,Gottesman SR,Alagha O,Todor R,Axiotis CA

更新日期：2005-07-01 00:00:00

abstract：:The efficacy of All-Trans Retinoic Acid (Atra) and Arsenic Trioxide (As(2)O(3)) in the treatment of Acute Promyelocytic Leukemia (APL) is well known. Further, these drugs inhibit cell growth and induce apoptosis in several cell lines, but few data are reported on leukemic blasts. The aim of this study was to evaluate ...

journal_title：Leukemia & lymphoma

authors： Cosenza M,Civallero M,Sacchi S,Marcheselli R,Pozzi S

更新日期：2005-02-01 00:00:00

abstract：:The hypomethylating agents azacitidine and decitabine are standard therapy for myelodysplastic syndromes (MDS), and are often used to treat patients with acute myeloid leukemia (AML) unlikely to benefit from cytotoxic chemotherapy. Switching hypomethylating agents after treatment failure is common, but this approach i...

journal_title：Leukemia & lymphoma

authors： Duong VH,Bhatnagar B,Zandberg DP,Vannorsdall EJ,Tidwell ML,Chen Q,Baer MR

更新日期：2015-06-01 00:00:00

abstract：:High dose chemotherapy with autologous stem cell transplantation (ASCT) improves outcomes in patients 65 years of age or less with multiple myeloma. Survival and costs in a cohort of 16 patients who received melphalan and prednisone as part of a clinical trial were compared with those of 36 patients referred to our ce...

journal_title：Leukemia & lymphoma

authors： Kouroukis CT,O'Brien BJ,Benger A,Marcellus D,Foley R,Garner J,Ingram C,Haines P,Henderson-O'Connor N,Meyer R

更新日期：2003-01-01 00:00:00

abstract：:Rituximab is known to affect T cell immune responses. We and others have reported expansions of T large granular lymphocytes (T-LGLs) in lymphoma patients after Rituximab. We report here the immunogenetic profiling of the T cell receptor (TR) gene repertoire in 14 patients who received Rituximab post allo-HCT and expl...

journal_title：Leukemia & lymphoma

authors： Papalexandri A,Karypidou M,Stalika E,Kotta K,Touloumenidou T,Zerva P,Paleta A,Mallouri D,Batsis I,Sakellari I,Kotsianidis I,Anagnostopoulos A,Hadzidimitriou A,Margaritis D,Stamatopoulos K

更新日期：2019-07-01 00:00:00

abstract：:The capacity to generate effective dendritic cells (DC) from adult acute lymphoblastic leukemia (ALL) patients in complete remission (CR) and off-therapy was investigated. Monocyte-derived DC cultured in the presence of granulocyte-macrophage colony-stimulating factor, interleukin (IL)-4 and tumor necrosis factor (TNF...

journal_title：Leukemia & lymphoma

authors： Maggio R,Peragine N,Calabrese E,De Propris MS,Intoppa S,Della Starza I,Ariola C,Vitale A,Foà R,Guarini A

更新日期：2007-02-01 00:00:00

abstract：:The natural history of the chronic phase (CP) of chronic myeloid leukemia (CML) and the high response rates achieved with BCR-ABL inhibitor therapy necessitate long-term evaluation of survival-based outcome measures. Prior to the availability of long-term BCR-ABL inhibitor data, short-term surrogate end points predict...

journal_title：Leukemia & lymphoma

authors： Akwaa F,Liesveld J

更新日期：2013-10-01 00:00:00

abstract：:Two patients presented with anasarca, fevers and sweats. Subsequent evaluation revealed aggressive lymphoproliferative disease. Both patients were treated with CHOP chemotherapy. One patient responded with spontaneous, vigorous diuresis and complete resolution of the edema. She relapsed two months later with recurrent...

journal_title：Leukemia & lymphoma

authors： Jillella AP,Day DS,Severson K,Kallab AM,Burgess R

更新日期：2000-07-01 00:00:00

abstract：:To distinguish the similarities or differences between T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), we retrospectively analyzed the clinical, immunophenotypic, cytogenetic, and molecular characteristics in 37 children diagnosed between December 1990 and December 2003. Compara...

journal_title：Leukemia & lymphoma

authors： Uyttebroeck A,Vanhentenrijk V,Hagemeijer A,Boeckx N,Renard M,Wlodarska I,Vandenberghe P,Depaepe P,De Wolf-Peeters C

更新日期：2007-09-01 00:00:00

abstract：:The epitope in the frame region (FR) of the immunoglobulin heavy chain variable region (IgHV) is a potential target for lymphoma immunotherapy. Our previous work identified a FR-derived nonapeptide (QLVQSGAEV) capable of in vitro eliciting anti-lymphoma specific cytotoxic T lymphocytes (CTLs) in lymphocytes from human...

journal_title：Leukemia & lymphoma

authors： Liu H,Cai P,Liu HX,Wang JL,Liu Q,Zhu P

更新日期：2011-09-01 00:00:00

abstract：:Classical Hodgkin's disease (HD) is a peculiar form of lymphoma characterized by a low frequency of tumor cells, the so-called Hodgkin (H) and Reed/Sternberg (RS) cells, embedded in a background of non-neoplastic (reactive) cells believed to be recruited and activated by H-RS cell-derived cytokines/chemokines. How the...

journal_title：Leukemia & lymphoma

authors： Aldinucci D,Olivo K,Lorenzon D,Poletto D,Gloghini A,Carbone A,Pinto A

更新日期：2005-03-01 00:00:00

abstract：:Myocyte enhancer factor 2C (MEF2C) encodes a transcription factor which is ectopically expressed in T-cell acute lymphoblastic leukemia (T-ALL) cell lines, deregulated directly by ectopically expressed homeodomain protein NKX2-5 or by loss of promoter regions via del(5)(q14). Here, we analyzed the MEF2C 5'-region, thu...

journal_title：Leukemia & lymphoma

authors： Nagel S,Venturini L,Meyer C,Kaufmann M,Scherr M,Drexler HG,Macleod RA

更新日期：2011-02-01 00:00:00

abstract：:Since rising serum lactate dehydrogenase (LDH) heralds progression in patients with lymphoma or myeloma we investigated the significance of its elevations during chemotherapy supported by granulocyte (G-) or Granulocyte-Macrophage (GM-) colony stimulating factors (CSF). To Exclude effects of resistant disease we analy...

journal_title：Leukemia & lymphoma

authors： Sarris AH,Majlis A,Dimopoulos MA,Younes A,Swann F,Rodriguez MA,McLaughlin P,Cabanillas F

更新日期：1995-05-01 00:00:00

abstract：:Dysregulation of MYBL2 has been associated to tumorigenesis and the S427G polymorphism could induce partial inactivation of MYBL2, associating it with cancer risk. It has previously been shown that MYBL2 was over-expressed in some acute myeloid leukemias (AML), portending poor prognosis. However, to date no studies ha...

journal_title：Leukemia & lymphoma

authors： Dolz S,García P,Llop M,Fuster Ó,Luna I,Ibáñez M,Gómez I,López M,Such E,Cervera J,Sanz MA,De Juan I,Palanca S,Murria R,Bolufer P,Barragán E

更新日期：2016-02-01 00:00:00

abstract：:Despite progress in AML therapy, most patients eventually relapse, even the ones with normal or favorable karyotype. Since survival is poor once relapse occurs, new genetic tools above karyotype at diagnosis are needed to predict leukemia free survival. Recently, Flt3/ITD has been reported as an independent marker for...

journal_title：Leukemia & lymphoma

authors： Ciolli S,Vannucchi AM,Leoni F,Nozzoli C,Longo G,Salati A,Pancrazzi A,Bianchi L,Gigli F,Bosi A

更新日期：2004-01-01 00:00:00

abstract：:Despite maturation arrest, blast cells in acute myeloid leukemia (AML) are often capable of expressing lineage-restricted (granulomonocytic or myelomastocytic) differentiation antigens. Tryptases are lineage-associated serine proteases primarily expressed in mast cells, and less abundantly in blood basophils. We have ...

journal_title：Leukemia & lymphoma

authors： Sperr WR,Hauswirth AW,Valent P

更新日期：2002-12-01 00:00:00

abstract：:Myeloperoxidase (MPO) has been shown to catalyze the in vitro degradation of vincristine (VCR). Given that MPO is a lysosomal enzyme that can be released into the circulation by both normal activated and leukemic myeloid cells, we investigated the possibility that sera from patients with acute myeloblastic leukemia (A...

journal_title：Leukemia & lymphoma

authors： Schlaifer D,Duchayne E,Demur C,Alvinerie P,Muller C,Attal M,Cooper MR,Payen C,Monsarrat B,Myers CE,Pris J,Laurent G

更新日期：1996-02-01 00:00:00

abstract：:We describe the patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the initial staging of patients with newly diagnosed grade 1-2 follicular lymphoma (FL) and its potential impact on treatment. Data were obtained from the National Comprehensive Cancer Network Non-Hodgkin Lymphoma...

journal_title：Leukemia & lymphoma

authors： Abou-Nassar KE,Vanderplas A,Friedberg JW,Abel GA,Niland J,Rodriguez MA,Czuczman MS,Millenson M,Crosby A,Gordon LI,Zelenetz AD,Kaminski M,Lacasce AS

更新日期：2013-10-01 00:00:00

abstract：:Analysis of the microRNA transcriptome following dexa- methasone treatment of the acute lymphocytic leukemia (ALL) cell line RS4;11 showed a global down-regulation of microRNA levels. MIR17HG was rapidly down-regulated following treatment, with chromatin immunoprecipitation (ChIP) analysis demonstrating the promoter t...

journal_title：Leukemia & lymphoma

authors： Harada M,Pokrovskaja-Tamm K,Söderhäll S,Heyman M,Grander D,Corcoran M

更新日期：2012-10-01 00:00:00

abstract：:The significant clinical activity of lenalidomide in relapsed CLL was first described several years ago. Since then the problems of tumor flare and tumor lysis have emerged, and upfront single agent studies have reported response rates that were perhaps a little disappointing. Interest in elucidating the place of lena...

journal_title：Leukemia & lymphoma

authors： Brown JR

更新日期：2010-08-01 00:00:00

abstract：:Out of 75 consecutive elderly AML patients who did not receive anti-leukemic treatment (52 pts) or failed to respond to differentiating agent (23 pts), 6 patients had survivals of 13.2 to 98 months with treatment restricted to supportive care. This cut-point is far longer than the median survival of the 235 elderly pa...

journal_title：Leukemia & lymphoma

authors： Baudard M,Legrand O,Marie JP,Zittoun R

更新日期：1999-08-01 00:00:00

abstract：:The mammalian target of rapamycin (mTOR) is an important protein kinase regulating cell survival and apoptosis. To determine whether genetic variations in mTOR are associated with risk of acute lymphoblastic leukemia (ALL) in Chinese children, we genotyped two tag single nucleotide poymorphisms (SNPs) in mTOR (rs2536 ...

journal_title：Leukemia & lymphoma

authors： Huang L,Huang J,Wu P,Li Q,Rong L,Xue Y,Lu Q,Li J,Tong N,Wang M,Zhang Z,Fang Y

更新日期：2012-05-01 00:00:00

abstract：:The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocytochemistry). Both methods gave reproducible and identical results when CPC were 1% or more. Using this limit, no CPC were observed in MGUS (0/11) and primary amyloid...

journal_title：Leukemia & lymphoma

authors： Zandecki M,Facon T,Preudhomme C,Canis F,Izydorczyk V,Lovi V,Hammad M,Bauters F,Cosson A

更新日期：1994-08-01 00:00:00

abstract：:Early and targeted antimicrobial therapy improves outcomes in patients with febrile neutropenia (FN). We evaluated the impact of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) on antimicrobial utilization in the management of FN. A cohort of patients with FN and hematological malignancy was iden...

journal_title：Leukemia & lymphoma

authors： Koh KC,Slavin MA,Thursky KA,Lau E,Hicks RJ,Drummond E,Wong PS,Worth LJ

更新日期：2012-10-01 00:00:00

abstract：:BCL6 is a transcriptional repressor often expressed constitutively in diffuse large B-cell lymphomas (DLBCL) due to mutations of its genomic locus. BCL6 mediates aberrant survival, proliferation, genomic instability and differentiation blockade in DLBCL cells. The biochemical study of BCL6 mediated gene repression has...

journal_title：Leukemia & lymphoma

authors： Parekh S,Privé G,Melnick A

更新日期：2008-05-01 00:00:00